ENT Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Appropriate Antibiotic Use for Acute Otitis Media

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy
Head & Neck, 04/06/09

Cohen EEW et al. - In a trial to assess the efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy, data suggest that primary chemoradiotherapy (CRT) is an effective treatment approach in pts with T4 oral cavity (OC) tumors including those with bony involvement producing LC, survival, and complication rates comparable to historical series.

Methods

A retrospective review of 4 multi-institutional phase II studies was performed estimating long-term toxicity, locoregional control (LC), progression-free survival (PFS), and overall survival (OS) of primary CRT.

Results

39 subjects were identified; 16 (42%) with bony involvement.
Median radiotherapy dose delivered to primary tumor was 74 Gy.
5-yr OS, PFS, and LC rates were 56%, 51%, and 75%, respectively.
69% of subjects with bony involvement never relapsed.
7 subjects developed osteoradionecrosis.
Bone involvement with primary tumor did not appear to be associated with increased risk of death, relapse, or long-term complication.

<< Previous
Burden of COPD, Asthma, and Concomitant COPD/Asthma Among Adults

Next >>
Antibacterial and antifungal properties of human cerumen